<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097980</url>
  </required_header>
  <id_info>
    <org_study_id>BT098-02</org_study_id>
    <secondary_id>CAD-BAFH-M99</secondary_id>
    <nct_id>NCT01097980</nct_id>
  </id_info>
  <brief_title>Trazodone for SSRI-sexual Dsyfunction</brief_title>
  <acronym>T-SSRI-SD</acronym>
  <official_title>The Efficacy of Trazodone for Selective Serotonin Reuptake Inhibitor-induced Sexual Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beitou Armed Forces Hospital, Taipei, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beitou Armed Forces Hospital, Taipei, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the efficacy of trazodone in the treatment of
      selective serotonin reuptake inhibitor(s) associated sexual dysfunction. The secondary
      domains assessed were the relationship between 5-HT2A polymorphism and treatment efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The differences between trazodone and placebo in the Arizona Sexual Experiences Scale-Chinese Version scale at the end of week 6 were used as the primary study outcomes.</measure>
    <time_frame>week 0 and week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The association between 5-HT2A polymorphism and the changes in Arizona Sexual Experiences Scale-Chinese Version scale were evaluated.</measure>
    <time_frame>week 6</time_frame>
    <description>The secondary domains assessed were the difference between trazodone and placebo in the Clinical Global Impression scale, 10-point Visual Analogue Scale, Hamilton Depression Rating Scale, and Hamilton Anxiety Rating Scale at the end of week 6. Besides, relationships between 5-HT2A polymorphism and the changes in Arizona Sexual Experiences Scale-Chinese Version scale were also evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Trazodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trazodone versus placebo in a randomized, double-blind manner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained</description>
    <arm_group_label>Trazodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria were:

          1. 20-65 years of age,

          2. receiving SSRI treatment for more than four weeks,

          3. minimal dose of fluoxetine, paroxetine, and citalopram are 20 mg/d, minimal dose of
             fluvoxamine and sertraline are 50 mg/d, and minimal dose of escitalopram is 10mg/d,

          4. developing sexual dysfunction based on the definition of Arizona Sexual
             Experience-Chinese Version.

        Exclusion criteria were:

          1. receiving other antidepressant agents,

          2. receiving antipsychotics,

          3. having a currently unstable medical condition such as unstable angina or uncontrolled
             diabetes,

          4. having any serious medical condition that affects sexual functioning such as epilepsy,
             serious head injury, brain tumor, HIV infection, Parkinson's disease, dementia,
             multiple sclerosis, or other neurological disorder,

          5. being pregnant or planning to become pregnant during the study period,

          6. experiencing psychotic symptoms,

          7. being comorbidity with substance abuse, (8) developing sexual dysfunction before
             receiving SSRIs treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuo-Tung Chiang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Psychiatry, Beitou Armed Forces Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, Beitou Armed Forces Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11243</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Stryjer R, Spivak B, Strous RD, Shiloh R, Harary E, Polak L, Birgen M, Kotler M, Weizman A. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol. 2009 Mar-Apr;32(2):82-4. doi: 10.1097/WNF.0B013E31816D1CDC.</citation>
    <PMID>18978492</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beitou Armed Forces Hospital, Taipei, Taiwan</investigator_affiliation>
    <investigator_full_name>Kuo-Tung Chiang</investigator_full_name>
    <investigator_title>Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>trazodone</keyword>
  <keyword>SSRI</keyword>
  <keyword>sexual dysfunction</keyword>
  <keyword>5-HT2A polymorphism</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

